AbbVie Inc (ABBV)vsCVS Health Corp (CVS)
ABBV
AbbVie Inc
$263.78
-0.02%
HEALTHCARE · Cap: $454.36B
CVS
CVS Health Corp
$90.27
-1.58%
HEALTHCARE · Cap: $121.07B
Smart Verdict
WallStSmart Research — data-driven comparison
CVS Health Corp generates 541% more annual revenue ($412.64B vs $64.39B). ABBV leads profitability with a 9.8% profit margin vs 1.2%. CVS appears more attractively valued with a PEG of 0.22. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CVS
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$263.78
$111.62 premium
Margin of Safety
+45.3%
Fair Value
$140.81
Current Price
$90.27
$50.54 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 188.8% YoY
Large-cap with strong market position
Generating 5.7B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
ROE of 6.2% — below average capital efficiency
1.2% margin — thin
Operating margin of 3.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : CVS
The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.22 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : CVS
The primary concerns for CVS are P/E Ratio, Return on Equity, Profit Margin. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
CVS carries more volatility with a beta of 0.58 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
CVS generates stronger free cash flow (5.7B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 67/100) and 10.2% revenue growth. CVS offers better value entry with a 45.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CVS Health Corp
HEALTHCARE · HEALTHCARE PLANS · USA
CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?